BackIdexx Laboratories Overview
Idexx Laboratories, Inc.

Idexx Laboratories Target Price

Analysts' average 12-month price target for Idexx Laboratories is $670.

Get informed when a big investor buys or sells

+ Follow

Share Price

$519.26

Average Target Price

$665.0028.1% upside

2 analysts in the last 4 months

High: $710 | Low: $620

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-11BarclaysGlen Santangelo$71036.7% upsideOpen
2026-07-27UBS$62019.4% upsideOpen
2026-04-28UBSAndrea Alfonso$64023.3% upsideOpen
2026-02-09Piper Sandler$75044.4% upsideOpen
2026-02-05BarclaysGlen Santangelo$80054.1% upsideOpen
2026-02-03UBSAndrea Alfonso$73040.6% upsideOpen
2026-02-03BTIG$80054.1% upsideOpen
2025-12-08BarclaysGlen Santangelo$85063.7% upsideOpen
2025-11-04Morgan Stanley$80555% upsideOpen
2025-11-04UBS$75044.4% upsideOpen
2025-11-04BTIG$83059.8% upsideOpen
2025-11-04JefferiesKeith Devas$83059.8% upsideOpen
2025-11-03Leerink Partners$78551.2% upsideOpen
2025-11-03Stifel NicolausJonathan Block$77549.3% upsideOpen
2025-10-31Stifel NicolausJonathan Block$70034.8% upsideOpen
2025-10-01UBSAndrea Alfonso$72038.7% upsideOpen
2025-08-05Morgan Stanley$72239% upsideOpen
2025-08-05BTIG$78551.2% upsideOpen
2025-08-04Stifel Nicolaus$64023.3% upsideOpen
2024-06-24Stifel NicolausJonathan Block$5101.8% downsideOpen
2023-02-08Barclays$59013.6% upsideOpen
2023-02-07J.P. Morgan$5505.9% upsideOpen
2023-02-07Atlantic Equities$60015.5% upsideOpen
2023-02-02Oppenheimer$24752.4% downsideOpen
2023-02-02Citigroup$26848.4% downsideOpen
2022-12-09Citigroup$27347.4% downsideOpen
2022-11-15Morgan Stanley$5434.6% upsideOpen
2022-06-24Stifel Nicolaus$5003.7% downsideOpen
2022-05-19Goldman Sachs$5302.1% upsideOpen
2022-05-06BarclaysBalaji Prasad$70034.8% upsideOpen

Idexx Laboratories (IDXX) FAQ

Idexx Laboratories's target price stands at $670. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $670 for IDXX implies 28.1% upside versus today's price ($519.26). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Idexx Laboratories's target price evolved across reporting periods, while the comparison chart places IDXX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Idexx Laboratories's reading of $670 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.